BioNTech SE
Stock Forecast, Prediction & Price Target
BioNTech SE (BNTX) stock Price Target by analysts
$127.25
Potential upside: 13.21%
BioNTech SE price prediction
What is BioNTech SE stock analysts` prediction?
BioNTech SE stock forecast: Based on 4 Wall Street analysts` predicted price targets for BioNTech SE in the last 3 months, the avarage price target is $127.25, with a high forecast of $NaN. The average price target represents a 13.21% change from the last price of $112.4.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
BioNTech SE stock Price Target by analysts
Full breakdown of analysts given BioNTech SE price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Cory Kasimov Evercore ISI | 0% 0/2 | 11 months ago | $125 11.20% upside | $80.8 | StreetInsider | Previous targets (1) |
Daina Graybosch Leerink Partners | 50% 1/2 | 11 months ago | $121 7.65% upside | $80.8 | StreetInsider | Previous targets (1) |
Chris Shibutani Goldman Sachs | 50% 1/2 | 11 months ago | $137 21.88% upside | $110.66 | StreetInsider | Previous targets (1) |
Etzer Darout BMO Capital | 0% 0/3 | 12 months ago | $126 12.09% upside | $108.97 | StreetInsider | Previous targets (2) |
Terence Flynn Morgan Stanley | 0% 0/2 | about 1 year ago | $145 29.00% upside | $113.05 | TheFly | Previous targets (1) |
Akash Tewari Jefferies | 0% 0/2 | about 1 year ago | $150 33.45% upside | $123.97 | StreetInsider | Previous targets (1) |
Tazeen Ahmad Bank of America Securities | 0% 0/1 | about 1 year ago | $150 33.45% upside | $123.4 | StreetInsider | Previous targets (0) |
Akash Tewari Jefferies | 0% 0/2 | about 1 year ago | $96 -14.59% downside | $105 | StreetInsider | Previous targets (1) |
Emmanuel Papadakis Deutsche Bank | 0% 0/1 | about 1 year ago | $95 -15.48% downside | $79.5 | TheFly | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/2 | about 1 year ago | $93 -17.25% downside | $78.36 | StreetInsider | Previous targets (1) |
Yifeng Liu HSBC | 50% 1/2 | about 1 year ago | $101 -10.14% downside | $82.01 | StreetInsider | Previous targets (1) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | over 1 year ago | $113 0.53% upside | $82.52 | StreetInsider | Previous targets (0) |
Cory Kasimov Evercore ISI | 0% 0/2 | over 1 year ago | $100 -11.03% downside | $92.72 | StreetInsider | Previous targets (1) |
Etzer Darout BMO Capital | 0% 0/3 | over 1 year ago | $122 8.54% upside | $91.53 | StreetInsider | Previous targets (2) |
Yifeng Liu HSBC | 50% 1/2 | over 1 year ago | $90 -19.92% downside | $91.83 | StreetInsider | Previous targets (1) |
Chris Shibutani Goldman Sachs | 50% 1/2 | over 1 year ago | $91 -19.03% downside | $91.99 | StreetInsider | Previous targets (1) |
William Maughan Canaccord Genuity | 0% 0/1 | over 1 year ago | $171 52.13% upside | $91.99 | StreetInsider | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/3 | over 1 year ago | $123 9.43% upside | $91.99 | StreetInsider | Previous targets (2) |
Unknown Goldman Sachs | N/A | over 2 years ago | $156 38.79% upside | $143.41 | Benzinga | N/A |
Mani Foroohar Leerink Partners | 100% 1/1 | almost 3 years ago | $81 -27.93% downside | $169.47 | Benzinga | Previous targets (0) |
Andrew Ang UBS | 100% 1/1 | over 3 years ago | $168 49.46% upside | $159.8 | Pulse 2.0 | Previous targets (0) |
Matthew Harrison Morgan Stanley | 0% 0/1 | over 3 years ago | $195 73.48% upside | $140.32 | TipRanks Contributor | Previous targets (0) |
Robert Burns H.C. Wainwright | 0% 0/1 | over 3 years ago | $298 165.12% upside | $175.29 | Pulse 2.0 | Previous targets (0) |
Arlinda Lee Canaccord Genuity | 0% 0/1 | over 3 years ago | $300 166.90% upside | $170.26 | Pulse 2.0 | Previous targets (0) |
Eliana Merle UBS | 100% 1/1 | over 3 years ago | $170 51.24% upside | $147.5 | StreetInsider | Previous targets (0) |
Suzanne van Voorthuizen Kempen & Co | 0% 0/1 | almost 4 years ago | $350 211.38% upside | $259.7 | TheFly | Previous targets (0) |
Daina Graybosch Leerink Partners | 50% 1/2 | almost 4 years ago | $253 125.08% upside | $284.21 | StreetInsider | Previous targets (1) |
Olga Smolentseva Bryan Garnier & Co Ltd | 100% 1/1 | about 4 years ago | $359 219.39% upside | $248.9 | Investing | Previous targets (0) |
BioNTech SE Financial Estimates
BioNTech SE Revenue Estimates
BioNTech SE EBITDA Estimates
BioNTech SE Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.97B N/A | $17.31B -8.77% | $3.81B -77.93% | Avg: $2.50B Low: $1.47B High: $3.27B avg. -34.45% | Avg: $2.54B Low: $1.77B High: $3.10B avg. 1.56% | Avg: $3.52B Low: $2.45B High: $4.30B avg. 38.71% | Avg: $4.33B Low: $3.02B High: $5.29B avg. 23.00% |
Net Income
% change YoY
| $10.29B N/A | $9.43B -8.33% | $930.3M -90.13% | Avg: $-500.88M Low: $-1.13B High: $92.59M avg. -153.84% | Avg: $-508.87M Low: $-1.39B High: $311.64M avg. -1.59% | Avg: $-409.97M Low: $-526.94M High: $-248.75M avg. 19.43% | Avg: $27.46M Low: $16.66M High: $35.30M avg. 106.69% |
EBITDA
% change YoY
| $14.97B N/A | $13.09B -12.52% | $1.08B -91.69% | Avg: $380.84M Low: $224.24M High: $498.60M avg. -64.98% | Avg: $386.79M Low: $269.78M High: $471.68M avg. 1.56% | Avg: $536.55M Low: $374.24M High: $654.30M avg. 38.71% | Avg: $659.98M Low: $460.33M High: $804.83M avg. 23.00% |
EPS
% change YoY
| $43.87 N/A | $38.08 -13.19% | $3.83 -89.94% | Avg: -$2.13 Low: -$4.67 High: $0.38 avg. -155.50% | Avg: -$2.13 Low: -$5.77 High: $1.28 avg. -0.36% | Avg: -$1.69 Low: -$2.17 High: -$1.02 avg. 20.83% | Avg: $0.11 Low: $0.07 High: $0.15 avg. 106.69% |
Operating Expenses
% change YoY
| $200.1M N/A | $135.9M -32.08% | $2.52B 1760.77% | Avg: $410.36M Low: $241.62M High: $537.25M avg. -83.77% | Avg: $416.77M Low: $290.70M High: $508.24M avg. 1.56% | Avg: $578.13M Low: $403.25M High: $705.02M avg. 38.71% | Avg: $711.13M Low: $496.01M High: $867.21M avg. 23.00% |
FAQ
What is BioNTech SE stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -7.32% in 2025-2028.
We have gathered data from 14 analysts. Their low estimate is -1.13B, average is -500.88M and high is 92.59M.
What is BioNTech SE stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 7.20% in 2025-2028.
We have gathered data from 14 analysts. Their low revenue estimate is $1.47B, average is $2.50B and high is $3.27B.
What is BioNTech SE stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -7.08% in 2025-2028.
We have gathered data from 14 analysts. Their low earnings per share estimate is -$4.67, average is -$2.13 and high is $0.38.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering BioNTech SE stock. The most successful analyst is Cory Kasimov.